Advancing the Cardiovascular Care of the Oncology Patient is organized by American College of Cardiology (ACC) and will be held from Jan 25 - 27, 2019 at The Ritz-Carlton, Washington, DC, Washington, Dist of Col, United States of America.
The target audience for this medical event is cardiologists, oncologists, internists and all members of the multi-professional care team (including advanced practice nurses, physician assistants, pharmacists, exercise physiologists) who are providing clinical care to the growing population of cancer patients and survivors with cardiovascular concerns.
Cardiovascular disease is the second leading cause of morbidity and mortality in cancer survivors. Since an estimated 14.5 million cancer patients and survivors have significant cardiovascular risk factors, it is critical for cardiologists, oncologists, and the entire multi-professional care team to stay on the leading edge of this rapidly evolving field. Advancing the Cardiovascular Care of the Oncology Patient provides clinicians and researchers with the tools needed to improve patient care in your everyday practice.
Over the past 3 years, the American College of Cardiology has joined forces with respected experts in the field of Cardio-oncology to develop a program covering the most relevant and required content for both the novice and advancing practitioner. Join us at Advancing the Cardiovascular Care of the Oncology Patient and engage with our growing community. Participate through interactive case discussions on evidence-based treatment strategies that address pre, intra and post-chemotherapy heart health. Throughout the course, you'll have the unique opportunity to engage with expert faculty and a network of colleagues centered around ensuring your patients receive the most informed care possible.
2019 Pre-conference Educational Seminar: Common Cancer Pharmacotherapies and the CV Patient will be held on Jan 25, 2019 at Heart House.
The 3-hour intensive session is devoted to common conventional and newer highly targeted cancer therapies. The focus of the course will include Anthracyclines, HER2-Targeted Therapies, VEGF-Targeted Therapies and Immunotherapies.
Pre-conference Registration Rate - $100.
Additional details will be posted as soon as they are available.